Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Craig M Horbinski

Showing results (71-80 of 83) with videos related to

Pageof 9
Sort By:
Biorxiv : the Preprint Server for Biology|July 28, 2023
NOTCH3 drives meningioma tumorigenesis and resistance to radiotherapyAbrar Choudhury, Martha A Cady, Calixto-Hope G Lucas, et al.
Cancer Discovery|May 14, 2024
Perivascular NOTCH3+ Stem Cells Drive Meningioma Tumorigenesis and Resistance to RadiotherapyAbrar Choudhury, Martha A Cady, Calixto-Hope G Lucas, et al.
Nature|July 6, 2017
Transcription elongation factors represent in vivo cancer dependencies in glioblastomaTyler E Miller, Brian B Liau, Lisa C Wallace, et al.
The Journal of Clinical Investigation|August 29, 2024
B cell-based therapy produces antibodies that inhibit glioblastoma growthSi Wang, Brandyn A Castro, Joshua L Katz, et al.
JCI Insight|May 30, 2023
The MIF promoter SNP rs755622 is associated with immune activation in glioblastomaTyler J Alban, Matthew M Grabowski, Balint Otvos, et al.
The Journal of Clinical Investigation|June 28, 2024
STING agonist 8803 reprograms the immune microenvironment and increases survival in preclinical models of glioblastomaHinda Najem, Spencer T Lea, Shashwat Tripathi, et al.
Nature Communications|June 6, 2024
Ultrasound-mediated delivery of doxorubicin to the brain results in immune modulation and improved responses to PD-1 blockade in gliomasVíctor A Arrieta, Andrew Gould, Kwang-Soo Kim, et al.
Neuro-Oncology|January 26, 2026
Integrated immune profiling of chordomas reveals spatially organized niches and functional heterogeneityVictor A Arrieta, J Kada Benotmane, Rebecca Du, et al.
Acta Neuropathologica|July 23, 2017
Immunohistochemical analysis of H3K27me3 demonstrates global reduction in group-A childhood posterior fossa ependymoma and is a powerful predictor of outcomePooja Panwalkar, Jonathan Clark, Vijay Ramaswamy, et al.
The Lancet. Oncology|September 4, 2025
The effect of TERT promoter mutation on predicting meningioma outcomes: a multi-institutional cohort analysisKarenna J Groff, Ruchit V Patel, Yang Feng, et al.
Pageof 9

Showing results (71-80 of 83) with videos related to

Sort By:
Pageof 9
Biorxiv : the Preprint Server for Biology|July 28, 2023
NOTCH3 drives meningioma tumorigenesis and resistance to radiotherapyAbrar Choudhury, Martha A Cady, Calixto-Hope G Lucas, et al.
Cancer Discovery|May 14, 2024
Perivascular NOTCH3+ Stem Cells Drive Meningioma Tumorigenesis and Resistance to RadiotherapyAbrar Choudhury, Martha A Cady, Calixto-Hope G Lucas, et al.
Nature|July 6, 2017
Transcription elongation factors represent in vivo cancer dependencies in glioblastomaTyler E Miller, Brian B Liau, Lisa C Wallace, et al.
The Journal of Clinical Investigation|August 29, 2024
B cell-based therapy produces antibodies that inhibit glioblastoma growthSi Wang, Brandyn A Castro, Joshua L Katz, et al.
JCI Insight|May 30, 2023
The MIF promoter SNP rs755622 is associated with immune activation in glioblastomaTyler J Alban, Matthew M Grabowski, Balint Otvos, et al.
The Journal of Clinical Investigation|June 28, 2024
STING agonist 8803 reprograms the immune microenvironment and increases survival in preclinical models of glioblastomaHinda Najem, Spencer T Lea, Shashwat Tripathi, et al.
Nature Communications|June 6, 2024
Ultrasound-mediated delivery of doxorubicin to the brain results in immune modulation and improved responses to PD-1 blockade in gliomasVíctor A Arrieta, Andrew Gould, Kwang-Soo Kim, et al.
Neuro-Oncology|January 26, 2026
Integrated immune profiling of chordomas reveals spatially organized niches and functional heterogeneityVictor A Arrieta, J Kada Benotmane, Rebecca Du, et al.
Acta Neuropathologica|July 23, 2017
Immunohistochemical analysis of H3K27me3 demonstrates global reduction in group-A childhood posterior fossa ependymoma and is a powerful predictor of outcomePooja Panwalkar, Jonathan Clark, Vijay Ramaswamy, et al.
The Lancet. Oncology|September 4, 2025
The effect of TERT promoter mutation on predicting meningioma outcomes: a multi-institutional cohort analysisKarenna J Groff, Ruchit V Patel, Yang Feng, et al.
Pageof 9